NBTX NASDAQ
Credit Risk of going bust: higher than 73% of companies Debt: 7.0% of company value Bonds: none of note held by US funds details ▾
Total debt $119.1M against a stock market value of $1.58B.
Distance to default 3.17 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $76.7M (short-term plus half of long-term), stock volatility 90.5%; Altman Z'' -0.10. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Paris, IF 75012
FR
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.